Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for non-culprit coronary lesions after ACS
NL-OMON52478Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial in acute coronary syndrome (ACS) and coronary arteriosclerosis comparing Evolocumab + high-intensity statin therapy with Placebo + high-intensity statin therapy (2 arms). Primary endpoints: Change in fractional flow reserve and Change in MaxLCBI4mm. Started Nov 2020; status: completed.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON52478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52478.